Literature DB >> 15564765

Long-term adaptation of renal ion transporters to chronic diuretic treatment.

Gheun-Ho Kim1.   

Abstract

Loop and thiazide diuretics are clinically useful to induce negative sodium balance. However, with chronic treatment, their effects tend to be blunted since the kidney adapts to diuretics. Molecular identification of the renal ion transporters has provided us with a new understanding of the mechanisms of intrarenal adaptation to diuretics at molecular levels. In the kidney, loop and thiazide diuretics are secreted from the proximal tubule via the organic anion transporter-1 (OAT1) and exert their diuretic action by binding to the Na-K-2Cl cotransporter type 2 (NKCC2) in the thick ascending limb and the Na-Cl cotransporter (NCC) in the distal convoluted tubule, respectively. Recent studies in animal models suggest that abundance of these ion transporters is affected by long-term diuretic administration. Downstream from the primary site of diuretic action, an increase in epithelial Na+ channel (ENaC) abundance is induced by chronic furosemide or hydrochlorothiazide treatment. This adaptation is consistent with previous reports showing cellular hypertrophy and increased Na+ absorption in distal tubular segments. The abundance of NKCC2 and NCC is increased by furosemide and hydrochlorothiazide, respectively. This compensatory upregulation suggests that either diuretic may activate the ion transporter within the primary site of action. In the proximal tubule, the abundance of OAT1 is increased by chronic treatment with furosemide or hydrochlorothiazide. This upregulation of OAT1 seems to be induced by substrate stimulation, lessening diuretic tolerance associated with long-term diuretic use. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15564765     DOI: 10.1159/000082314

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  19 in total

1.  Management of Cardio-Renal Syndrome and Diuretic Resistance.

Authors:  Frederik H Verbrugge; Wilfried Mullens; W H Wilson Tang
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-02

Review 2.  New insights into combinational drug therapy to manage congestion in heart failure.

Authors:  Frederik Hendrik Verbrugge; Lars Grieten; Wilfried Mullens
Journal:  Curr Heart Fail Rep       Date:  2014-03

3.  Impaired glucose tolerance, glucagon, and insulin responses in mice lacking the loop diuretic-sensitive Nkcc2a transporter.

Authors:  Lisa Kelly; Mohammed M Almutairi; Shams Kursan; Romario Pacheco; Eduardo Dias-Junior; Hayo Castrop; Mauricio Di Fulvio
Journal:  Am J Physiol Cell Physiol       Date:  2019-07-31       Impact factor: 4.249

4.  Furosemide diminishes ¹⁸F-fluoroethylcholine uptake in prostate cancer in vivo.

Authors:  H Christian Rischke; Teresa Beck; Werner Vach; Gesche Wieser; Anca L Grosu; Wolfgang Schultze-Seemann; Philipp T Meyer; Cordula A Jilg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-06-21       Impact factor: 9.236

Review 5.  Diuretic use in renal disease.

Authors:  Domenic A Sica
Journal:  Nat Rev Nephrol       Date:  2011-12-20       Impact factor: 28.314

6.  Physiologically Based Pharmacokinetic Modeling of Fimasartan, Amlodipine, and Hydrochlorothiazide for the Investigation of Drug-Drug Interaction Potentials.

Authors:  Su-Jin Rhee; Hyun A Lee; Soyoung Lee; Eunwoo Kim; Inseung Jeon; Im-Sook Song; Kyung-Sang Yu
Journal:  Pharm Res       Date:  2018-10-15       Impact factor: 4.200

Review 7.  Renal autoregulation: new perspectives regarding the protective and regulatory roles of the underlying mechanisms.

Authors:  Rodger Loutzenhiser; Karen Griffin; Geoffrey Williamson; Anil Bidani
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-05       Impact factor: 3.619

Review 8.  Efficacy and safety of loop diuretic therapy in acute decompensated heart failure: a clinical review.

Authors:  Laura Leto; Nadia Aspromonte; Mauro Feola
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

9.  The CUL3/KLHL3-WNK-SPAK/OSR1 pathway as a target for antihypertensive therapy.

Authors:  Mohammed Z Ferdaus; James A McCormick
Journal:  Am J Physiol Renal Physiol       Date:  2016-04-13

Review 10.  Regulatory control of the Na-Cl co-transporter NCC and its therapeutic potential for hypertension.

Authors:  Nur Farah Meor Azlan; Maarten P Koeners; Jinwei Zhang
Journal:  Acta Pharm Sin B       Date:  2020-09-22       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.